Generex had two financing deals last January where shareholders noted how the terms were overly dilutive. Joe’s response was that was a no brainer to sell shares at .70 on the dollar because it was to help immediately bring Excellagen to market to bring in revenue. This was reiterated numerous times, so I don’t think it’s ridiculous to expect to see even a small fraction of anticipated revs especially when the company noted strong demand, sold out initial batches, and checks in hand.

For Altucell, Generex needs 2.3+ cash at closing plus a lot of shares. They had bridge financing and the K shows smaller financing arrangements are periodically made so I’m not following how closing couldn’t occur in the time period stated by the company.

The S1 has been filed. It’s blank as far as terms on offered shares and warrants. One item we see is .92 on a dollar but we really need to see that all fleshed out with accompanying warrants etc because $40 mil is a lot to raise in one transaction from these depleted share prices. And my concern was that even talking of raising so much now would cause investors to get out. Who is the fund or investor? That’s interesting to consider.